Bibliografisk note

Funding Information:
The EHSF exome sequencing and cellular/molecular profiling project will be supported by funding from a third industrial party (pending agreement finalization), the European Academy of Dermatology and Venereology project grant PPRC-2020-8 to CCZ and the Brandenburg Medical School Theodor Fontane project grant 19630051 to Dr. Georgios Nikolakis, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany and CCZ. The Department of Dermatology, Zeeland University Hospital, Roskilde, Denmark; the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands; the Department of Dermatology, Université Libre de Bruxelles, Brussels, Belgium; and the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany are healthcare providers of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin-ALLOCATE Skin group).

Funding Information:
The EHSF exome sequencing and cellular/molecular profiling project will be supported by funding from a third industrial party (pending agreement finalization), the European Academy of Dermatology and Venereology project grant PPRC‐2020‐8 to CCZ and the Brandenburg Medical School Theodor Fontane project grant 19630051 to Dr. Georgios Nikolakis, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany and CCZ. The Department of Dermatology, Zeeland University Hospital, Roskilde, Denmark; the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands; the Department of Dermatology, Université Libre de Bruxelles, Brussels, Belgium; and the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany are healthcare providers of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin‐ALLOCATE Skin group).

Funding Information:
All authors declare that none of the mentioned conflicts of interest had any influence to this manuscript. GBEJ reports personal fees from Abbvie, Coloplast, Chemocentryx, Kymera, LEO pharma, Incyte, InflaRx, Novartis, Sanofi, UCB, VielaBio, and grants from Afyx, CSL Behring, InflaRx, Janssen‐Cilag, LEO Foundation, Novartis, Regeneron, Sanofi, UCB. GBEJ is the Vice President of the EHSF e.V., co‐coordinator of the ALLOCATE Skin group of the ERN Skin and vice chair of the ARHS Task Force group of the EADV. He is the Editor‐in‐Chief of Dermatology. VdM reports honoraria for advisory board participation from BMS, Leo Pharma, Sanofi. She is the co‐ordinator of the ALLOCATE Skin group of the ERN Skin. VB reports speaker/consultancy/advisory boards honoraria from AbbVie, Biogen, Difa Cooper, Galderma and Mylan. MA reports consulting fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz and UCB. EPP reports speaker and advisory board honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Janssen‐Cilag, Galderma, InflaRx, Novartis, UCB, Regeneron and Pfizer. His employer has received investigator‐initiated grants from AbbVie, Celgene, Janssen‐Cilag and UCB. CCZ reports consultancy/advisory boards disease‐relevant honoraria from AbbVie, Bayer, Incyte, Inflarx, Janssen‐Cilag, Novartis, Regeneron and UCB. He has received speaker fees from AbbVie and UCB. CCZ is President of the EHSF e.V., coordinator of the ALLOCATE Skin group of the ERN Skin and chair of the ARHS Task Force group of the EADV. He is Editor of the EADV News. CCZ is co‐copyright holder of IHS4 on behalf of the EHSF e.V. His employer has received disease‐relevant grants from AbbVie, Boehringer‐Ingelheim, InflaRx, Novartis and UCB for his participation as clinical investigator.

Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.